Lanreotide (Somatuline Depot)

Somatuline Depot (lanreotide) is covered for long‑term treatment of acromegaly (non‑oncology) in patients with inadequate response to or who are not candidates for surgery/radiotherapy or who have tumor‑related complications; oncology uses are not covered here. Coverage requires documentation of acromegaly and prior surgery/radiotherapy status, a pre‑treatment IGF‑1 above the laboratory age/gender upper limit, prescription by or consultation with an endocrinologist, GH/IGF‑1 monitoring (including levels 6 weeks after any extended‑interval dosing change), and is approved up to 12 months with typical initiation at 90 mg every 4 weeks and dose adjustments per GH/IGF‑1.

"FDA-Approved Non-Oncology Indication: Somatuline Depot is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for wh..."